Lung Cancer Considered

By IASLCScience

Lung Cancer Considered episodes

February 24 • Live from TTLC 2026: Emerging Molecular Targets in Non-Small Cell Lung Cancer (NSCLC)
In this episode of Lung Cancer Considered, host Dr. Narjust Florez explores the evolving landscape of emerging molecular targets in NSCLC with Dr. Kelsey Pan and Rajat Thawani, live from the Targeted Therapies of Lung Cancer (TTLC) 2026 conference. The discussion highlights rare oncogenic drivers with a focus on clinical evidence, resistance mechanisms and trial design. The episode also addresses biomarker testing, the role of next-generation sequencing and liquid biopsy, and what the next five years may hold for precision treatment strategies in NSCLC.
Guests:
Kelsey Pan, MD, MPH
Assistant Professor of Medicine
Department of Hematology & Oncology, Thoracic Medical Oncology Section
Emory University Winship Cancer Institute
Rajat Thawani, MD
Assistant Professor of Medicine
Division of Hematology and Oncology
Knight Cancer Institute, OHSU
43 min
February 17 Virtual Tumor Board: Current Treatment for Small Cell Lung Cancer (SCLC)
This episode of Lung Cancer Considered focuses on a case of a patient with extensive stage SCLC. SCLC is a highly lethal subtype of lung cancer, accounting for about 13% of new lung cancer diagnoses with high variability based on geography and socioeconomic factors. The standard treatment for ES-SCLC had been platinum + etoposide for several decades, but over the past 7 years, we have had several new paradigm shifts that have led to real survival gains. To discuss current state of the art management,
Guests:
Raffaele Califano, Consultant at the Christie and Professor of Medical Oncology at Manchester University in the United Kingdom.
Dr. Jessica Menis, thoracic medical oncologist at University Hospital of Verona, in Verona, Italy
38 min
February 17 IASLC Global Policy Update
This episode examines the role public policy plays in impacting lung cancer treatment and research. The world has made tremendous progress in the treatment of lung cancer over the past decade, and much of that progress is the result of supportive public health policies. As we look to the future, healthcare policy is sure to play an even bigger role in further improving patient outcomes, but many challenging barriers exist on a global scale.
Host: Dr. Stephen Liu
Guests:
Professor Andreas Charalambous, Chair of the Department of Nursing and Professor of Oncology and Palliative Care at the Cyprus University of Technology.
Professor Nicole Rankin, Head of the Evaluation and Implementation Science Unit at the Melbourne School of Population and Global Health of the University of Melbourne
Dr. Samuel Kareff, thoracic medical oncologist at the Eugene M. and Christine E. Lynn Cancer Institute and Clinical Assistant Professor at Florida Atlantic University
55 min
February 13 • LCC in Cantonese: Updates in Surgical Approaches and Techniques in Early-Stage Lung Cancer
As part of IASLC’s ongoing series of Lung Cancer Considered podcasts in world languages, Dr. Molly Li moderates a discussion in Cantonese with two expert cardiothoracic surgeons, Dr. Ben Li, Professor from The First Affiliated Hospital of Guangzhou Medical University and, and Dr. Calvin Ng, Professor from the Chinese University of Hong Kong. The discussion: reviews surgical management of early-stage NSCLC, including VATS, and lobar versus sublobar resection; and explores novel technologies including endobronchial therapy and tubeless anesthesia.
Host: Molly Li, MD Clinical Assistant Professor
Department of Clinical Oncology, CUHK, Hong Kong
Guests:
Shuben Li, MD, PhD
Professor, Department of Thoracic Surgery
National Center for Respiratory Medicine
The First Affiliated Hospital of Guangzhou Medical University
Calvin S.H. Ng, BSc MBBS, MD
Environmental Foundation Professor of Thoracic Surgery
Department of Surgery
The Chinese University of Hong Kong (CUHK)
55 min
February 10 What do I need to know about AI? Discussing the Role of AI in Thoracic Oncology
This episode of Lung Cancer Considered examines how artificial intelligence is being incorporated into patient care and what the future holds for this emerging technology.
We will be discussing:
• Is AI the right move for oncology care?
• What is the impact on patient care and our patient expert’s experience?
• And how can we learn more about AI?
Guest:
Dr. Sandip Patel, is a professor of Medicine at UCSD and a nationally recognized leader in precision cancer medicine and innovation. He specializes in early-phase clinical trials and immunotherapy, with a focus on developing innovative treatments for patients with advanced lung cancer. Today, we’re excited to welcome him to the podcast to discuss the future of AI in cancer care, in general, and in thoracic oncology in particular.
46 min
February 03 Lung Cancer Considered: Lung Cancer Care in Areas of Conflict and War
This episode of Lung Cancer Considered, hosted by Dr. Narjust Florez, examines the challenges of delivering lung cancer care in areas affected by war and displacement with guests Dr. Julie Gralow and Dr. Rafal Dziadziuszko. The discussion addresses disrupted diagnosis and treatment, heightened inequities, and unique environmental exposures that may increase lung cancer risk in conflict settings. The episode also highlights emerging opportunities through global collaboration, adaptable care models, and shared responsibility across the oncology community.
Guests:
Dr. Julie Gralow, Chief Medical Officer and Executive Vice President of the American Society of Clinical Oncology (ASCO). She is also the founder of the Women's Empowerment Cancer Advocacy Network (WE CAN) and an expert in global oncology.
Rafał Dziadziuszko, M.D., Ph.D., professor of medicine, Head, Department of Oncology & Radiotherapy and Early Phase Clinical Trials Centre, Medical University of Gdańsk in Poland
48 min
January 30 LCC in Turkish: Virtual Tumor Board Immunotherapy for NSCLC
As part of IASLC’s ongoing series of Lung Cancer Considered podcast episodes in world languages, Dr. Ece Cali moderates a discussion in Turkish with Dr. Irfan Çiçin and Dr. Fulden Yumuk. The episode is part of our Virtual Tumor Board series and focuses on immunotherapy for non-small cell lung cancer (NSCLC).
38 min
January 20 Lung Cancer Considered: IASLC Hot Topic in Basic & Translational Science Meeting Highlights
This episode reviews the IASLC 2025 Hot Topic in Basic and Translational Science Conference, which focused on unraveling precancer and early-stage lung cancer, a theme that really captures where the field is heading. Instead of reacting to advanced disease.
Guests:
Dr. Triparna Sen, a professor of Internal Medicine at The Ohio State University and the director of the Lung Cancer Preclinical Therapeutics Platform at the OSUCCC – James. She also serves as the associate director of research for the Division of Medical Oncology. Her research focuses on understanding and therapeutically targeting mechanisms of therapy resistance and lineage plasticity in lung cancer, with a primary emphasis on small cell lung cancer (SCLC) and biologically aggressive subsets of non-small cell lung cancer.
Dr. Aaron Tan is a physician-scientist whose work bridges early detection, translational biology, and clinical relevance in lung cancer. Dr. Tan is a Medical Oncologist at the National Cancer Centre Singapore (NCCS), where he is involved in early drug development, genomics with a focus on EGFR mutated lung cancer, and clinical implementation of liquid biopsy including for advanced lung cancer and MRD in early-stage lung cancer.
36 min
January 16 Lung Cancer Considered in Portuguese: Junior Faculty Perspective
As part of IASLC’s Lung Cancer Considered World Language Series, guest host Dr. Maria Cecilia Mathias leads a discussion in Portuguese about the junior faculty perspective with Dr. Maria Thereza Starling and Dr. Paula Duarte.
45 min
January 06 Lung Cancer Considered: Role of General Media in Lung Cancer Research
In this episode of Lung Cancer Considered, host Dr. Stephen Liu is joined by CNN Medical Correspondent Meg Tirrell and WTOP reporter Neal Augenstein to discuss the role of the media in lung cancer awareness and perception. Traditional media, including television and radio, do much to shape the public perception of lung cancer and healthcare in general. Meg Tirrell and Neal Augenstein share their experiences reporting in the health sector, establishing trust with their audiences in the face of uncertainty, and distilling complex medical information to the general public.
32 min

About Lung Cancer Considered

From the publisher's feed

Dr. Stephen Liu and Dr. Narjust Florez host Lung Cancer Considered, the podcast of The International Association for the Study of Lung Cancer (IASLC). IASLC is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 11,000 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information.